A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

• Status: Completed
• Trial end date: 2002-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Alendronate

Criteria

Inclusion Criteria:

• Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease

Exclusion Criteria:

• Patient cannot stand or sit upright for at least 30 minutes

• Patient has difficulty swallowing or problems with digestive system